About ROCA

Screening for Ovarian Cancer

The ROCA Test helps clinicians identify whether a woman may have ovarian cancer.

Eligibility

The ROCA Test is for women who are:

  • Postmenopausal and over 50 years old
  • Between 35 and 85 years who are considered high risk due to family history of ovarian or breast cancer; are of Ashkenazi Jewish descent with a known family history of ovarian or breast cancer; or have a mutation in the BRCA1 or BRCA2 or Lynch Syndrome genes

Performance of the ROCA Test as reported in UKCTOCS

The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was a 15-year clinical trial, involving over 200,000 women. One arm of this 15-year randomised controlled trial investigated the use of the multimodal screening (MMS, ROCA Test followed by transvaginal ultrasound) to detect ovarian cancer in asymptomatic postmenopausal women between 50 and 74 years old.1,2,3

These results, published to date in the Journal of Clinical Oncology and The Lancet, show:

  • High sensitivity: 85.8%3
  • High specificity: 99.8%3
  • High positive predictive value (PPV): 20.8%3

Performance using the MMS or an ultrasound strategy (USS) are compared below4:

asco-stats-comparison

*iEO/T/PP: invasive epithelial/tubal/primary peritoneal

Learn more with our ROCA Test FAQs


References:

  1. Menon U, Gentry-Maharaj A, Hallett R, et al: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol; 10: 327- 40, 2009.
  2. Menon U, Ryan A, Kalsi J, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol 2015; 33: 2062–71. 
  3. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016; 387: 944 – 956..
  4. Menon U, Ryan A, Burnell M, et al. Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS. J Clin Oncol 34, 2016 (suppl; abstr 5507)